NanoCon Newswire
Aug. 24, 2006 (Emeryville, Calif.) — Nanomix Inc., a leading nanoelectronic detection company commercializing high-value diagnostic and monitoring applications, today announced the appointment of Dr. Michael D. Cable as Vice President, Platform Development to lead the company’s efforts in detection platform optimization for a variety of applications. In this position, Dr. Cable will report to David Macdonald, President and Chief Executive Officer.
Dr. Cable has over 20 years experience with a broad range of instrumentation and detection technologies related to medical diagnostic and monitoring applications. After earning a BS in Chemistry and Physics from Iowa State University, Dr. Cable obtained his Ph.D. from University of California Berkeley in Nuclear Chemistry and Physics. He has published extensively and holds multiple patents.
Prior to joining Nanomix, Dr. Cable was Vice President, Research and Development at Fovi Optics where he was involved with non-invasive glucose detection. He has been a consultant to Quantum Dot Corporation and held the position of Vice President and Chief Technology Officer at Xenogen. Dr. Cable has also held positions of increasing responsibility at the University of Rochester and Lawrence Livermore National Laboratory.
“We are thrilled with the addition of Mike to our management team,” said Nanomix CEO David Macdonald, “He will further enhance our detection platform and our ability to effectively execute project plans.”
About Nanomix
Nanomix is a leading nanoelectronic detection company launching a portfolio of devices based on Sensation™ technology. These scaleable devices use ultra-sensitive carbon nanotube detection elements combined with proprietary chemistries. They can be deployed across a broad range of industrial and medical applications where valuable attributes – low power consumption, small size, and high sensitivity offer significant performance advantages and enable unprecedented access to critical information. Nanomix is located in Emeryville, California. For additional information, please visit the Nanomix web site at www.nano.com